Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study

Next Previous
X
Search
Trial Profile

Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Pharmacokinetics
  • Acronyms INVICTAN-1
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 01 Aug 2017 Primary endpoint of AUC of the analyte in plasma from time zero extrapolated to infinity has been met, according to results published in the Expert Opinion on Investigational Drugs.
    • 01 Aug 2017 Results published in the Expert Opinion on Investigational Drugs
    • 01 Aug 2017 Status changed from recruiting to discontinued according to results published in the Expert Opinion on Investigational Drugs.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top